Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies

NCT04752826 is registered in ClinicalTrials.gov with BioInvent International AB as lead sponsor.

NCT NCT04752826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies
Lead sponsor
BioInvent International AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 25, 2021
Completion date
December 31, 2028
Enrollment
250 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, melanoma, ovarian cancer, t-cell lymphoma